

IN THE CLAIMS

1. (Currently Amended) A method for preventing a transplantation-associated immune response in a subject, comprising:

administering to said subject an effective amount of a conjugate comprising methotrexate and albumin at a methotrexate:albumin molar ratio of ~~1:1000 to 2:1~~ 0.9 to 1.1:1,

wherein said transplantation is an organ transplantation selected from the group consisting of kidney, heart and liver transplantation.

2. (Canceled)

3. (Previously Presented) The method of claim 1, wherein said transplantation-associated immune response is graft versus host disease (GVHD).

4. (Previously Presented) The method of claim 3, wherein said GVHD is an acute GVHD.

5. (Previously Presented) The method of claim 3, wherein said GVHD is a chronic GVHD.

6. (Previously Presented) The method of claim 1, wherein said transplantation is a bone marrow transplantation.

7. (Canceled)

8. (Previously Presented) The method of claim 1, wherein said transplantation is an allogeneic transplantation.

9-11. (Canceled)

12. (Previously Presented) The method of claim 1, wherein said albumin is human albumin.

13. (Previously Presented) The method of claim 1, wherein said albumin is a native human albumin.

14. (Canceled).

15. (Currently Amended) A method for preparing a conjugate comprising methotrexate and albumin, said method comprising:

activating a carboxyl group-containing methotrexate with 1-ethyl-3-(3-dimethylamino-propyl) carbonyldiimide in an organic solvent; and

reacting said activated carboxyl group-containing methotrexate with albumin at a methotrexate:albumin molar ratio of ~~10:1 to 1:10~~ 1.5:1 to 1:1.5.

16-19. (Canceled)

20. (Previously Presented) The method of claim 15, wherein said methotrexate is activated with 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide in an anhydrous organic solvent by heating.

21-22. (Canceled)